34 results about "CD1" patented technology

Provided are CD-1 presented antigens, compositions, cells, inhibitors and methods relating to the use of hydrophobic antigen presentation by CD1 molecules, including:methods for detecting the presence of a CD1-presented hydrophobic antigen in a sample;methods for isolating such CD1-presented antigens and the isolated antigens;vaccines containing CD1-presented antigens and vaccination methods;methods of blocking CD1 antigen presentation;methods of identifying and/or isolating CD1 blocking agents and the isolated CD1 blocking agents;methods of inducing CD1 expression; andT-cells for use in the methods disclosed.

The invention discloses a corrosive agent which is used for showing the dislocation of II-VI group semiconductor materials and the corrosive agent is provided with the component ratio of 80ml: 6 to 10ml: 10 to 15ml: 0 to 5ml: 5.1g: 2.0 to 7.0g of H2O to HCl to HNO 3 to HF to K2Cr2O7 to CrO3; wherein, the II-VI group semiconductor materials are ZnyCd1-yTe materials and Hg1-xCdxTe thin film materials which develop by taking the ZnyCd1-yTe materials as the substrate extension; the corrosion method comprises the pretreatment of the eroded samples, the dislocation erosion and the post treatment of the eroded samples; compared with two present common Schaake and Chen corrosive agents specially used for showing the dislocation of the Hg1-xCdxTe thin film materials, the invention has the advantages of bigger shape of a corrosive pit and clear rules and background, and showing the dislocation corrosive pit of the substrate materials Cd1-yZnyTe, which has great significance in the study of the dislocation corresponding relations of the extension and the substrate.

Provided are CD-1 presented antigens, compositions, cells, inhibitors and methods relating to the use of hydrophobic antigen presentation by CD1 molecules, including: methods for detecting the presence of a CD1-presented hydrophobic antigen in a sample; methods for isolating such CD1-presented antigens and the isolated antigens; vaccines containing CD1-presented antigens and vaccination methods; methods of blocking CD1 antigen presentation; methods of identifying and/or isolating CD1 blocking agents and the isolated CD1 blocking agents; methods of inducing CD1 expression; and T-cells for use in the methods disclosed herein.

The invention discloses a method for simultaneously detecting precise ball hinge ball-head eccentricity and ball arm space attitude. At present, the method for effectively measuring ball hinge ball-head eccentricity and ball arm space attitude is few. The method comprises the following steps: acquiring distance between an emitting point of an ultrasonic emitter and a receiving point of each of four ultrasonic receivers, decoupling an included angle between a bar arm central axis and an Z axle and the included angle between a projection line of the bar arm central axis on an XOY plane and a X axle through a geometric principle; detecting capacitance CG1 of a spherical-crown electrode G1 and the capacitance CG3 of the spherical-crown electrode G3 to obtain the differential capacitance therebetween; detecting capacitance CG2 of a spherical-crown electrode G2 and the capacitance CG4 of the spherical-crown electrode G4 to obtain the differential capacitance therebetween; detecting the capacitance CD1 of the spherical-crown electrode D1 and the capacitance C2 of the spherical-crown electrode D2 to obtain the differential capacitance therebetween; and obtaining X, Y and Z values of the ball eccentricity. The ball arm space attitude of the ball hinge is acquired in real time based on the ultrasonic ranging principle, and the eccentricity of ball head of the ball hinge ball-head can beaccurately acquired based on the spherical capacitance principle.

The invention provides methods for the administration of an anti-CD 1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.

The invention relates to a method and a device for compressing a free space in a cadmium zinc telluride crystal growing crucible through double sealing sleeves and belongs to the technical field of special crystal growth. The method has the main technical scheme that Cd, Zn and Te raw materials which meet Cd1-xZnxTe (x is 0.04 to 0.8) and have the purity being 99.99999 percent are charged into a quartz crucible, a secondary sealing sleeve and a primary sealing sleeve are sequentially placed into the quartz crucible, the vacuum pumping is carried out until the pressure is 2.0*10<-4>Pa, and the quartz crucible is sealed and knotted at the primary sealing sleeve part. The sealed crucible is placed into a material blending furnace, the temperature is slowly raised to 500 DEG C, after the heat insulation for a certain time, the temperature is slowly raised, and the material blending and the heat insulation are carried out after the melting point of materials is reached. The temperature is slowly lowered to the room temperature, and the material blending is completed. Then, the crucible is taken out, the crucible is subjected to secondary pipe sealing at the secondary sealing sleeve part. The primary sealing sleeve part at the tail part is cut off, and the crucible containing CdZnTe materials is placed into a crystal growth furnace for carrying out single crystal growth. The size compression on the free space during the crystal growth is realized through using the double sealing sleeves by the secondary pipe sealing method, and in the subsequent single crystal growth process, the formation of Cd vacant sites in crystals can be effectively inhibited, so the performance of the crystals is improved.

The invention relates to a manipulated professional antigen presenting cell (APC) having increased expression of a CD1 type II molecule, preferably at least a CD1d molecule, relative to a control non manipulated cell. The invention further relates to the use of PPARg modulators in the preparation of a pharmaceutical composition or kit for the treatment of a disease treatable by activation of CD1d restricted T-cells, e.g. in autoimmune diseases, allergies, post-transplant conditions or infectious diseases, or in the treatment of a neoplastic disease, e.g. skin cancer, hematological tumors, colorectal carcinoma, and therapeutic compositions and kits therefor. Furthermore, the invention relates to methods of manipulating professional APCs and kits therefor.

Pathogenic polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies is inhibited by binding molecules that specifically interfere with CD1 antigen, but do not activate signaling (blocking agents), or by molecules that bind to the T cell antigen receptor on T cells that recognize CD1. When CD1 mediated signaling is thus blocked, the T cell response is diminished, resulting in reduced polyclonal B cell activation and reduced immunoglobulin class switching to pathogenic autoantibodies.

The invention provides a luminescent material with a core-shell structure. A rare earth luminescent material is taken as a core, and a semiconductor Cd1-xZnxS is taken as a shell; the rare earth luminescent material takes rare earth ions as a luminescent center; and the range of Zn component in the Cd1-xZnxS is as follows: x is not less than 0 and less than 1. The semiconductor material has strong absorption against photons which are higher than a band gap, a quasi-continuous energy band structure allows a semiconductor to have a very high absorption coefficient in a very wide spectral range, and electrons excited by the high-energy photons can effectively relax to the bottom of a conduction band for downward transition luminescence. Therefore, the prepared luminescent material with the core-shell structure has the advantages of excellent light conversion performance and high luminescence efficiency. The luminescent material provided by the invention adopts a full-solid reaction method combining hot pressure sintering and high-temperature annealing, any solvent is not added in the whole process, the introduction of compound inclusions containing C-H and C-O bonds is avoided, and the relatively high luminescence efficiency is further ensured.

The invention discloses a streptococcus suis SBP-bac-5 gene deletion strain and a construction method and application thereof, the streptococcus suis SBP-bac-5 gene deletion strain is SS delta SBP-bac-5 containing no resistance maker, and the preservation number is CGMCC No.10076. Rec A homologous recombination system is used, temperature-sensitive suicide plasmid pSET4s as a carrier is used for deletion of a gene coded by the streptococcus suis type 7 strain SBP-bac-5 to obtain the streptococcus suis SBP-bac-5 gene deletion strain, and SBP-bac-5 protein expression can be destroyed. Compared with a parent strain, the streptococcus suis type 7 SS delta SBP-bac-5 strain is weaker in toxicity and safe to animals. A vaccine is prepared by use of recombinant bacteria for immunization of CD1 mice, the experimental results show that: the streptococcus suis recombinant bacteria vaccine can effectively induce production of specific humoral immune response, so that the immunized mice can be protected against S.suis (streptococcus suis) attacks, and bacteria multiplication in the body can be effectively prevented. The engineering bacteria provides an important basis for the development of vaccine of streptococcus suis vaccines.

The invention discloses a radioactive anti-peptide mutant protein and a preparation and purification method thereof. By adopting the method, the purity of a protein can be remarkably improved, and convenience can be brought to industrial production. The invention further provides a radioactive anti-peptide mutant protein. The mutant protein is generated by replacing amino acid sequences between ND1 and CD1 on the basis of a radioactive anti-peptide protein CBLB502, and the mutant protein has an amino acid sequence of SEQ ID NO:2 as shown in the specification, and the stability of the mutant protein is remarkably prior to that of the CBLB5-2 protein in the prior art.

The disclosure relates to methods and compositions for improving homing of cells including mesenchymal stem cells (MSCs). Compositions include compounds described herein as capable of inducing expression by MSCs of cell surface homing ligand molecules such as CD1 la, promoting increased firm adhesion by MSCs in an in vitro shear flow assay, increasing binding to an adhesion molecule such as E-selectin or ICAM-1, and/or demonstrating anti-inflammatory activity upon in vivo systemic administration in cell therapy using human MSCs. Also described are screening methods to identify small molecule compounds for improving a homing function of MSCs.

The invention discloses a novel mouse visual evoked potential recording method. According to the method, the VEP with good waveform and large amplitude can be recorded, and the influence of the position of the active electrode on the VEP is large. In a C57 or CD1 optic nerve pinch injury model mouse with retinal ganglion cell deletion and a Brn3bAP/AP mutant mouse, the VEP amplitude is obviously reduced. The method disclosed by the invention is very reliable and stable, and is particularly suitable for detecting visual response of reduced RGC quantity, dysfunction or brain connection disorder. Compared with an existing subcutaneous method (SUB), the method has the advantages that the VEP which is relatively stable, good in waveform and larger in amplitude can be recorded; compared with a skull pre-implantation screw recording method, the method has the advantage that damage of pre-implantation screws to mouse brain tissues can be reduced.

T cells are transfected with a recombinant RNA molecule that encodes at least one of an alpha chain and a beta chain of a CD1b restricted T cell receptor. Preferably, the so prepared T cells are used as a cell-based therapeutic composition to treat tuberculosis.